• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by Oragenics Inc.

    6/30/25 1:28:23 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGEN alert in real time by email
    S-1/A 1 forms-1a.htm S-1/A

     

    As filed with the Securities and Exchange Commission on June 30, 2025

     

    Registration No. 333-288225

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Amendment No. 1

    to

    FORM S-1

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    ORAGENICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Florida   59-3410522

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    1990 Main Street, Suite 750

    Sarasota, Florida 34236

    (813) 286-7900

    (Address, including zip code, and telephone number, including area code, of principal executive offices)

     

    Janet Huffman, Chief Executive Officer and Chief Financial Officer

    Oragenics, Inc.

    1990 Main Street, Suite 750

    Sarasota, Florida 34236

    (813) 286-7900

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    With copies to:

     

    Mark A. Catchur, Esq.

    Julio C. Esquivel, Esq.

    Shumaker, Loop & Kendrick, LLP

    101 East Kennedy Boulevard

    Suite 2800

    Tampa, Florida 33602

    Telephone: (813) 229-7600

    Facsimile: (813) 229-1660

     

    Ralph V. DeMartino, Esq.

    Marc Rivera, Esq.

    ArentFox Schiff LLP

    1717 K Street NW

    Washington, DC 20006

    Telephone: (202) 350-3643

    Facsimile: (202) 857-6395

     

    Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that the Registration Statement shall thereafter become effective in accordance with Section 8(A) of the Securities Act of 1933, or until this registration statement shall become effective on such date as the Commission, acting pursuant to section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Pre-Effective Amendment No. 1 (this “Amendment”) to the Registration Statement on Form S-1 of Oragenics, Inc. (File No. ) (the “Registration Statement”) is being filed as an exhibit-only filing to file a form of Securities Purchase Agreement to the exhibits and exhibit index. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement (the Exhibit Index), the form of Securities Purchase Agreement (filed herewith as Exhibit 10.27) and the signature page to the Registration Statement. The prospectus and the balance of Part II of the Registration Statement are unchanged and have been omitted.

     

     

     

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    (a) Exhibit Index

     

            Incorporated by Reference    

    Exhibit

    number

      Exhibit description   Form   File no.   Exhibit  

    Filing

    date

     

    Filed

    herewith

                             
    1.1   Form of Placement Agent Agreement   S-1   333-288225   1.1   6/23/25    
                             
    3.1   Amended and Restated Articles of Incorporation as amended prior to December 29, 2017 (including certificates of designation of Series A, B and C Preferred Stock).   8-K   001-32188   3.1   12/29/17    
                             
    3.2   Articles of Amendment to Amended and Restated Articles of Incorporation dated effective December 29, 2017.   8-K   001-32188   3.2   12/29/17    
                             
    3.3   Articles of Amendment to Amended and Restated Articles of Incorporation effective January 19, 2018.   8-K   001-32188   3.1   1/19/18    
                             
    3.4   Articles of Amendment to Amended and Restated Articles of Incorporation.   8-K   001-32188   3.4   6/26/18    
                             
    3.5   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.5   2/28/22    
                             
    3.6   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.1   1/23/23    
                             
    3.7   Amendment to Articles of Incorporation for Certificate of Designation of Series F Convertible Preferred Stock   8-K   001-32188   3.1   12/8/23    
                             
    3.8   Amendment to Articles of Incorporation to Increase Common Stock   8-K   001-32188   3.1   12/15/23    
                             
    3.9   Amendment to Articles of Incorporation to Effectuate Reverse stock Split   8-K   001-32188   3.1   5/28/25    
                             
    3.10   Form of Certificate of Designation of Preferences, Rights and Designations of Series H Convertible Preferred Stock   S-1   333-288225   3.10   6/23/25    
                             
    3.11   Bylaws   SB-2   333-100568   3.2   10/16/02    
                             
    3.12   First Amendment to Bylaws   8-K   001-32188   3.1   6/9/10    
                             
    3.13   Second Amendment to Bylaws   8-K   001-32188   3.1   8/24/10    

     

    II-1

     

     

    3.14   Third Amendment to Bylaws   8-K   001-32188   3.9   2/28/22    
                             
     4.1   Specimen Stock Certificate   8-K   001-32188   4.1   1/23/23    
                             
    4.2   Form of Common Stock Warrant   8-K   001-32118   4.1   11/9/17    
                             
    4.3   Form of Warrant to purchase shares of Common Stock.   S-1/A   333-224950   4.2   7/9/18    
                             
    4.4   Warrant Agency Agreement   8-K   001-32188   4.2   7/17/18    
                             
    4.5   Warrant dated May 1, 2020   8-K   001-32188   4.1   5/4/20    
                             
    4.6   Form of Placement Agent Warrant.   8-K   001-32188   4.1   6/26/24    
                             
    4.7   Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934   10-K   001-32188   4.8   3/29/24    
                             
    4.8   Form of Series H Warrant   S-1   333-288225   4.8   6/23/25    
                             
    4.9   Form of Warrant Agent Agreement   S-1   333-288225   4.9   6/23/25    
                             
    5.1   Opinion of Shumaker, Loop & Kendrick, LLP   S-1   333-288225   5.1   6/23/25    
                             
    10.1   Non-exclusive intellectual property and biological materials license agreement with the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health.*   10-Q   001-32188   10.2   8/14/20    
                             
    10.2   National Research Council (NRC) Canada Technology License Agreement (dated July 26, 2021) and Amendment One (dated September 2, 2021).*   10-Q   001-32188   10.0   11/15/21    
                             
    10.3   NRC Technology License Amendment 2   10-K   001-32188   10.6   3/24/22    
                             
    10.4   NRC Technology License Amendment 3   10-K   001-32188   10.7   3/24/22    
                             
    10.5   2012 Equity Incentive Plan. +   8-K   001-32188   4.1   10/25/12    
                             
    10.6   First Amendment to 2012 Equity Incentive Plan. +   8-K   001-32188   4.2   5/5/17    

     

    II-2

     

     

    10.7   Second Amendment to 2012 Equity Incentive Plan. +   8-K   001-32188   4.3   12/29/17    
                             
    10.8   Third Amendment to 2012 Equity Incentive Plan. +   8-K   001-32188   4.4   6/26/18    
                             
    10.9   Fourth Amendment to 2012 Equity Incentive Plan. +   8-K   001-32188   4.5   6/21/19    
                             
    10.10   Form of Employee Stock Option Agreement. +   10-K   001-32188   10.26   3/26/13    
                             
    10.11   Form of Consultant Stock Option Agreement. +   10-K   001-32188   10.27   3/26/13    
                             
    10.12   Form of Notice of Grant of Stock Options and Stock Option Award Agreement (Employee). +   8-K   001-32188   10.1   3/18/15    
                             
    10.13   Form of Notice of Grant of Stock Options and Stock Option Award Agreement (Directors). +   10-K   001-32188   10.23   3/4/20    
                             
    10.14   Form of Director Restricted Stock Award Agreement. +   8-K   001-32188   10.3   3/18/15    
                             
    10.17   2021 Equity Incentive Plan+   8-K   001-32188   10.1   2/28/22    
                             
    10.18   First Amendment to 2021 Equity Incentive Plan   8-K   001-32188   4.2   12/15/23    
                             
    10.19   Second Amendment to 2021 Equity Incentive Plan   8-K   001-32188   4.3   12/13/24    
                             
    10.20   Form Stock Option Award Agreement (Directors)+   8-K   001-32188   10.2   2/28/22    
                             
    10.21   Form Stock Option Award Agreement (Employees)+   8-K   001-32188   10.3   2/28/22    
                             
    10.22   Form Stock Option Award Agreement (Consultants)+   8-K   001-32188   10.4   2/28/22    
                             
    10.25   At-the-Market Sales Agreement between the Company and Dawson James Securities dated October 11, 2024   8-K   001-32188   1.1   10/15/24    
                             
    10.26   Janet Huffman Employment Agreement   8-K   001-32188   10.1   5/2/25    
                             
    10.27   Form of Securities Purchase Agreement                   X
                             
    21.1   Subsidiaries of Registrant   10-K   001-32188   21.1   3/24/22    
                             
    23.1   Consent of Cherry Bekaert LLP, an Independent Public Accounting Firm                   X
                             
    23.2   Consent of Shumaker, Loop & Kendrick, LLP (included in Exhibit 5.1)   S-1   333-288225   23.2   6/23/25    
                             
    24.1   Powers of Attorney (included on signature page).   S-1   333-288225   24.1   6/23/25    
                             
    107   Filing Fee Table   S-1   333-288225   107   6/23/25    

     

      * Confidential treatment has been granted as to certain portions of this exhibit pursuant to Rule 406 of the Securities Act of 1933, as amended, or Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
         
      + Executive management contract or compensatory plan or arrangement.
         
      ** Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

     

    II-3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Sarasota, State of Florida on June 30, 2025.

     

      ORAGENICS, INC.
         
      By: /s/ Janet Huffman
        Janet Huffman
        President, Chief Executive (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer)

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities indicated and on June 30, 2025.

     

    Signature   Title
         
    /s/ Janet Huffman   President Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer)
    Janet Huffman    
         
    *    
    Charles L. Pope   Executive Chairman and Director
         
    *    
    Robert C. Koski   Director
         
    *    
    Frederick W. Telling   Director
         
    *    
    Alan W. Dunton   Director
         
    *    
    John Gandolfo   Director

     

    By: /s/ Janet Huffman  
      Janet Huffman  
      Attorney-in-Fact  

     

    II-4

     

     

    Get the next $OGEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oragenics Completes Approximately $16.5 Million Offering

      SARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximately $16.5 million. As part of the transaction, Oragenics issued 660,000 shares of its Series H Convertible Preferred Stock, no par value, together with Warrants to purchase up to 660,000 additional shares of Series H Convertible Preferred Stock. Each unit, consisting of one share of Preferred Stock and one Warrant, was sold

      7/2/25 4:15:00 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

      SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company's Series H Convertible Preferred Stock ("Preferred Stock"), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the "Warrants"). The combined public Offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00 (the "Offering"). The Preferr

      7/1/25 8:31:01 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

      SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania. These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild

      6/10/25 8:30:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Odyssey Health, Inc. sold $30,407 worth of Common Stock - OGEN (7,044 units at $4.32), closing all direct ownership in the company (SEC Form 4)

      4 - ORAGENICS INC (0001174940) (Issuer)

      6/18/25 5:10:06 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Odyssey Health, Inc. sold $43,600 worth of Common Stock - OGEN (10,000 units at $4.36), decreasing direct ownership by 59% to 7,044 units (SEC Form 4)

      4 - ORAGENICS INC (0001174940) (Issuer)

      6/16/25 6:01:26 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Odyssey Health, Inc. claimed ownership of 249,623 units of Series F Preferred Stock and claimed ownership of 17,044 shares (SEC Form 3)

      3 - ORAGENICS INC (0001174940) (Issuer)

      6/16/25 5:54:50 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs initiated coverage on Oragenics with a new price target

      Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

      6/3/21 6:23:39 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    SEC Filings

    See more
    • Oragenics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - ORAGENICS INC (0001174940) (Filer)

      7/2/25 4:30:18 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Oragenics Inc.

      424B5 - ORAGENICS INC (0001174940) (Filer)

      7/2/25 8:15:24 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Oragenics Inc.

      EFFECT - ORAGENICS INC (0001174940) (Filer)

      7/1/25 12:15:12 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

      SC 13G/A - ORAGENICS INC (0001174940) (Subject)

      11/14/24 7:29:57 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

      SC 13G/A - ORAGENICS INC (0001174940) (Subject)

      11/14/24 3:59:00 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Oragenics Inc.

      SC 13G - ORAGENICS INC (0001174940) (Subject)

      9/11/24 7:45:36 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Financials

    Live finance-specific insights

    See more
    • Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

      TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

      2/12/21 8:00:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

      SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

      2/24/25 8:30:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

      SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

      5/22/24 8:00:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care